Suppression of experimental allergic encephalomyelitis by administration of 5-IODO-6-Amino-1,2,benzopyrone. A novel inhibitor of poly (ADP-ribose) synthetase

Gwen S. Scott, Paul Hake, Andrew L. Salzman, Csaba Szabo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introdaction: Experimental allergic encephatomyelitis (EAE) and it's human counterpart, multiple sclerosis (MS), are central nervous system (CNS) disorders of unknown aetiology. Much evidence exists implicating a role for inflammatory mediators in the pathogencsis of EAE [Hartung et al. J. Neuroimmunol. 1992; 40: 197]. Furthermore, recent investigations have demonstrated peroxynitrite involvement in disease development [Hooper et al. Proc. Natl. Acad. Sci USA 1997; 94: 2528-2533). Although peroxynitrite has been proposed as a mediator of EAE die precise mechanisms through which the molecule exerts its effects remain undefined. Previous studies have demonstrated that peroxynitrite can cause cytotoxicity via DNA single strand-breakage and poly (ADP-ribose) synthetase (PARS) activation [Szabó et al. Proc. NatL Acad. Sci. USA 1996; 93: 1753-1758]. We have, therefore, examined the effect of the novel PARS inhibitor, 5-iodo-6-tmino-1 1,2-beozopyrone (INH2BP) [Szabó et al. Int J. Oncol. 1997; 10: 1093] on the neurological development of EAE. Methods: Male Lewis rats (200-250g) inoculated for EAE were orally administered INH2BP (200mg/kg body weight) or vehicle (0.5 % rocthylcdhuose) once daily from days 7 to 11 post-inoculation (P.L). Animals neurological disease signs were leuiued daily on a severity scale from 0 to 4 [Scott et al., Inflamm. Res. 19%; 45: 524]. Results: Table: Neurological disease symptoms in EAE-sensitised Lewis rats following treatment with INH2BP or vehicle Group Incidence of Mean Day of Mean Number of EAE Disease Disease Rats Onset Severity Paralysed/To ± S.E.M. ± S.E.M. tal Vehicle 8/8 11 ± 0.2 2.3 ± 0.2 2/8 INH2BP 5/8 13 ± 0.5 0.9 ± 0.30/8p<0.01 Mann Whitney U test Conclusions: In conclusion, administration of INH2BP suppressed the development of neurolgical signs of EAE Thus, our data indicate the involvement of PARS activation in the pathogenesis of this disease. Further work is required to rally elucidate the precise role of PARS activation in the aetiology of EAE.

Original languageEnglish (US)
JournalCritical Care Medicine
Volume26
Issue number1 SUPPL.
StatePublished - 1998
Externally publishedYes

Fingerprint

Poly Adenosine Diphosphate Ribose
Autoimmune Experimental Encephalomyelitis
Ligases
Peroxynitrous Acid
Animal Diseases
Central Nervous System Diseases
Nonparametric Statistics
Multiple Sclerosis
Body Weight
6-amino-1,2-benzopyrone
DNA
Incidence

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Suppression of experimental allergic encephalomyelitis by administration of 5-IODO-6-Amino-1,2,benzopyrone. A novel inhibitor of poly (ADP-ribose) synthetase. / Scott, Gwen S.; Hake, Paul; Salzman, Andrew L.; Szabo, Csaba.

In: Critical Care Medicine, Vol. 26, No. 1 SUPPL., 1998.

Research output: Contribution to journalArticle

@article{335b50e13b1a4897b67b802a401aaa16,
title = "Suppression of experimental allergic encephalomyelitis by administration of 5-IODO-6-Amino-1,2,benzopyrone. A novel inhibitor of poly (ADP-ribose) synthetase",
abstract = "Introdaction: Experimental allergic encephatomyelitis (EAE) and it's human counterpart, multiple sclerosis (MS), are central nervous system (CNS) disorders of unknown aetiology. Much evidence exists implicating a role for inflammatory mediators in the pathogencsis of EAE [Hartung et al. J. Neuroimmunol. 1992; 40: 197]. Furthermore, recent investigations have demonstrated peroxynitrite involvement in disease development [Hooper et al. Proc. Natl. Acad. Sci USA 1997; 94: 2528-2533). Although peroxynitrite has been proposed as a mediator of EAE die precise mechanisms through which the molecule exerts its effects remain undefined. Previous studies have demonstrated that peroxynitrite can cause cytotoxicity via DNA single strand-breakage and poly (ADP-ribose) synthetase (PARS) activation [Szab{\'o} et al. Proc. NatL Acad. Sci. USA 1996; 93: 1753-1758]. We have, therefore, examined the effect of the novel PARS inhibitor, 5-iodo-6-tmino-1 1,2-beozopyrone (INH2BP) [Szab{\'o} et al. Int J. Oncol. 1997; 10: 1093] on the neurological development of EAE. Methods: Male Lewis rats (200-250g) inoculated for EAE were orally administered INH2BP (200mg/kg body weight) or vehicle (0.5 {\%} rocthylcdhuose) once daily from days 7 to 11 post-inoculation (P.L). Animals neurological disease signs were leuiued daily on a severity scale from 0 to 4 [Scott et al., Inflamm. Res. 19{\%}; 45: 524]. Results: Table: Neurological disease symptoms in EAE-sensitised Lewis rats following treatment with INH2BP or vehicle Group Incidence of Mean Day of Mean Number of EAE Disease Disease Rats Onset Severity Paralysed/To ± S.E.M. ± S.E.M. tal Vehicle 8/8 11 ± 0.2 2.3 ± 0.2 2/8 INH2BP 5/8 13 ± 0.5 0.9 ± 0.30/8p<0.01 Mann Whitney U test Conclusions: In conclusion, administration of INH2BP suppressed the development of neurolgical signs of EAE Thus, our data indicate the involvement of PARS activation in the pathogenesis of this disease. Further work is required to rally elucidate the precise role of PARS activation in the aetiology of EAE.",
author = "Scott, {Gwen S.} and Paul Hake and Salzman, {Andrew L.} and Csaba Szabo",
year = "1998",
language = "English (US)",
volume = "26",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Suppression of experimental allergic encephalomyelitis by administration of 5-IODO-6-Amino-1,2,benzopyrone. A novel inhibitor of poly (ADP-ribose) synthetase

AU - Scott, Gwen S.

AU - Hake, Paul

AU - Salzman, Andrew L.

AU - Szabo, Csaba

PY - 1998

Y1 - 1998

N2 - Introdaction: Experimental allergic encephatomyelitis (EAE) and it's human counterpart, multiple sclerosis (MS), are central nervous system (CNS) disorders of unknown aetiology. Much evidence exists implicating a role for inflammatory mediators in the pathogencsis of EAE [Hartung et al. J. Neuroimmunol. 1992; 40: 197]. Furthermore, recent investigations have demonstrated peroxynitrite involvement in disease development [Hooper et al. Proc. Natl. Acad. Sci USA 1997; 94: 2528-2533). Although peroxynitrite has been proposed as a mediator of EAE die precise mechanisms through which the molecule exerts its effects remain undefined. Previous studies have demonstrated that peroxynitrite can cause cytotoxicity via DNA single strand-breakage and poly (ADP-ribose) synthetase (PARS) activation [Szabó et al. Proc. NatL Acad. Sci. USA 1996; 93: 1753-1758]. We have, therefore, examined the effect of the novel PARS inhibitor, 5-iodo-6-tmino-1 1,2-beozopyrone (INH2BP) [Szabó et al. Int J. Oncol. 1997; 10: 1093] on the neurological development of EAE. Methods: Male Lewis rats (200-250g) inoculated for EAE were orally administered INH2BP (200mg/kg body weight) or vehicle (0.5 % rocthylcdhuose) once daily from days 7 to 11 post-inoculation (P.L). Animals neurological disease signs were leuiued daily on a severity scale from 0 to 4 [Scott et al., Inflamm. Res. 19%; 45: 524]. Results: Table: Neurological disease symptoms in EAE-sensitised Lewis rats following treatment with INH2BP or vehicle Group Incidence of Mean Day of Mean Number of EAE Disease Disease Rats Onset Severity Paralysed/To ± S.E.M. ± S.E.M. tal Vehicle 8/8 11 ± 0.2 2.3 ± 0.2 2/8 INH2BP 5/8 13 ± 0.5 0.9 ± 0.30/8p<0.01 Mann Whitney U test Conclusions: In conclusion, administration of INH2BP suppressed the development of neurolgical signs of EAE Thus, our data indicate the involvement of PARS activation in the pathogenesis of this disease. Further work is required to rally elucidate the precise role of PARS activation in the aetiology of EAE.

AB - Introdaction: Experimental allergic encephatomyelitis (EAE) and it's human counterpart, multiple sclerosis (MS), are central nervous system (CNS) disorders of unknown aetiology. Much evidence exists implicating a role for inflammatory mediators in the pathogencsis of EAE [Hartung et al. J. Neuroimmunol. 1992; 40: 197]. Furthermore, recent investigations have demonstrated peroxynitrite involvement in disease development [Hooper et al. Proc. Natl. Acad. Sci USA 1997; 94: 2528-2533). Although peroxynitrite has been proposed as a mediator of EAE die precise mechanisms through which the molecule exerts its effects remain undefined. Previous studies have demonstrated that peroxynitrite can cause cytotoxicity via DNA single strand-breakage and poly (ADP-ribose) synthetase (PARS) activation [Szabó et al. Proc. NatL Acad. Sci. USA 1996; 93: 1753-1758]. We have, therefore, examined the effect of the novel PARS inhibitor, 5-iodo-6-tmino-1 1,2-beozopyrone (INH2BP) [Szabó et al. Int J. Oncol. 1997; 10: 1093] on the neurological development of EAE. Methods: Male Lewis rats (200-250g) inoculated for EAE were orally administered INH2BP (200mg/kg body weight) or vehicle (0.5 % rocthylcdhuose) once daily from days 7 to 11 post-inoculation (P.L). Animals neurological disease signs were leuiued daily on a severity scale from 0 to 4 [Scott et al., Inflamm. Res. 19%; 45: 524]. Results: Table: Neurological disease symptoms in EAE-sensitised Lewis rats following treatment with INH2BP or vehicle Group Incidence of Mean Day of Mean Number of EAE Disease Disease Rats Onset Severity Paralysed/To ± S.E.M. ± S.E.M. tal Vehicle 8/8 11 ± 0.2 2.3 ± 0.2 2/8 INH2BP 5/8 13 ± 0.5 0.9 ± 0.30/8p<0.01 Mann Whitney U test Conclusions: In conclusion, administration of INH2BP suppressed the development of neurolgical signs of EAE Thus, our data indicate the involvement of PARS activation in the pathogenesis of this disease. Further work is required to rally elucidate the precise role of PARS activation in the aetiology of EAE.

UR - http://www.scopus.com/inward/record.url?scp=0005514760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0005514760&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0005514760

VL - 26

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1 SUPPL.

ER -